Pyxis Oncology, Inc. (PYXS) — As of October 31, 2026

Not investment advice.

Company Snapshot

Pyxis Oncology, Inc. (Nasdaq: PYXS) is a Boston-based, clinical-stage biopharmaceutical company (founded 2019, listed on Nasdaq in 2021) developing next-generation therapeutics for difficult-to-treat solid tumors via antibody-drug conjugate (ADC) and immuno-oncology platforms. Its lead candidate is micvotabart pelidotin (MICVO), formerly PYX-201, an ADC that targets extradomain-B of fibronectin (EDB+FN). [10], [20]

As of the October 30, 2026 close, PYXS traded at ~$1.81 with a market capitalization of ~$225.8M. [16], [17] The stock has been highly volatile: down ~22.3% over the past month and ~47.1% over the trailing year, while sitting well below its 52-week high of $5.55. [16]